Heart Failure Pharmacotherapy Across the TAVR Continuum

The authors investigate the role of guideline-directed medical therapy (GDMT) in managing heart failure across the continuum of transcatheter aortic valve replacement (TAVR) procedures, highlighting the need for optimized pharmacotherapy despite persistent myocardial disease post-TAVR. They emphasize the potential benefits of specific drug classes, particularly renin-angiotensin system inhibitors (RASi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), while identifying key uncertainties regarding timing and patient selection. The review calls for further randomized trials to establish effective implementation strategies for GDMT in TAVR patients.